Kronos Bio
New York, US · Founded 2017 · Delaware corporation · 4 known investors
Biotech
Founders & leadership
NB
Norbert Bischofberger, Ph.D.Executive
CW
Christopher WilfongExecutive
Board
RB
Rebecka Belldegrun, M.D.Board director
OS
Otello Stampacchia, Ph.D.Board director
DM
AS
Arie S. Belldegrun, M.D.Board director
JA
JC
John C. Martin, Ph.D.Board director
Investors · 4
Reported raises · per SEC filings
Form D private placements$123M disclosed across 2 rounds · 2018–2019
▶$105MraisedJul 2019 · 50 investors · BiotechnologyRule 506(b)
▶$105MraisedJul 2019 · 50 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jacob LovenDirector
- Rebecka Belldegrun, M.D.Director
- Norbert Bischofberger, Ph.D.Executive Officer, Director
- John C. Martin, Ph.D.Director
- Philip GutryExecutive Officer
- David M. TanenExecutive Officer, Director, Promoter
- Sean AlgeoExecutive Officer
- Joshua A. KazamDirector
- Otello Stampacchia, Ph.D.Director
- Arie S. Belldegrun, M.D.Director
- Offering amount
- $105M
- Amount sold
- $105M
- Proceeds to insiders
- $360K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$18MraisedJun 2018 · 32 investors · BiotechnologyRule 506(b)
▶$18MraisedJun 2018 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rebecka Belldegrun, M.D.Director
- Otello Stampacchia, Ph.D.Director
- David M. TanenExecutive Officer, Director, Promoter
- John C. Martin, Ph.D.Director
- Norbert Bischofberger, Ph.D.Executive Officer, Director
- Arie S. Belldegrun, M.D.Director
- Christopher WilfongExecutive Officer
- Joshua A. KazamDirector
- Offering amount
- $18M
- Amount sold
- $18M
- Proceeds to insiders
- $360K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapBioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
bio25 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
Northwest Biotherapeutics19 shared keywordsNorthwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines, marketed under the DCVax platform, that use activated dendritic cells to treat a range of solid tumor cancers. Its product lines include DCVax-L, DCVax-Direct, and DCVax-Prostate.
Belenosbio18 shared keywordsBelenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU. Its pipeline includes BEL512 (targeting TSLP and IL-13) and BEL536 (targeting OX40L and IL-13), both aimed at modulating type 2 inflammation.
Companies competing with Kronos Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- Who are Kronos Bio's investors?
- Kronos Bio's investors include EcoR1 Capital, GV (Google Ventures), Nextech Invest, Vida Ventures.
- How much funding has Kronos Bio raised?
- Kronos Bio has disclosed $123M raised across 2 rounds.
- Where is Kronos Bio headquartered?
- Kronos Bio is headquartered in New York, US.